Mallinckrodt PLC | Income Statement

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Sales/Revenue
2,205
2,540
2,923
3,381
3,222
3,216
Cost of Goods Sold (COGS) incl. D&A
1,179
1,337
1,300
1,521
1,560
1,739
Gross Income
1,026
1,204
1,623
1,860
1,662
1,476
SG&A Expense
775
932
1,101
1,162
1,167
1,234
EBIT
251
271
-
698
495
243
Unusual Expense
101
567
197
81
137
3,944
Non Operating Income/Expense
5
14
36
1
69
11
Interest Expense
20
83
256
385
369
370
Pretax Income
126
363
107
233
62
4,052
Income Tax
69
45
129
256
1,710
430
Consolidated Net Income
58
319
235
489
1,771
3,622
Net Income
58
319
235
489
1,771
3,622
Net Income After Extraordinaries
57
318
147
334
1,408
3,637
Net Income Available to Common
59
319
322
548
1,773
3,607
EPS (Basic)
1.02
4.92
2.75
5.77
21.80
42.94
Basic Shares Outstanding
58
65
116
111
98
84
EPS (Diluted)
1.02
4.92
2.75
5.77
21.80
42.94
Diluted Shares Outstanding
58
65
117
112
98
84
EBITDA
390
547
1,164
1,512
1,303
1,095
Non-Operating Interest Income
-
2
1
1
5
8
Other After Tax Income (Expense)
-
-
2
-
-
-

About Mallinckrodt

View Profile
Address
3 Lotus Park
Staines-Upon-Thames Surrey TW18 3AG
United Kingdom
Employees -
Website http://mallinckrodt.com
Updated 07/08/2019
Mallinckrodt Plc operates as a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments.